A novel controlled release formulation based on calcium sulphate as drug carrier loaded with the antiandrogen 2-hydroxiflutamide as the active pharmaceutical agent was injected locally into the prostate in patients with prostate cancer. Single-voxel and 2D MRSI using a surface coil were used to investigate the treatment efficiency. The results demonstrate usefulness of both MRS techniques to detect metabolic atrophy caused by long-term local hormone-deprivation therapy. The presence of metabolic atrophy reflects the antitumor effects of the study drug formulation 6 weeks after the intraprostatic injections.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords